TL;DR
Get self-care and calm essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA has opened a request for information on how early-phase clinical trials of ibogaine drug products could be designed, including safeguards for dosing and patient safety. Comments are due November 20, 2026; the agency says the responses may inform drug-development approaches, but the request does not approve ibogaine as a treatment.
The U.S. Food and Drug Administration is seeking public comments and data on possible designs for early-phase clinical trials of ibogaine drug products, including how researchers should select doses and monitor safety. The request is intended to inform drug development; it does not authorize ibogaine as a treatment or establish that it is safe or effective.
The agency’s request for information asks for input on four areas: study design and patient populations; dose selection and escalation; safety measures; and ethical and independent oversight. The FDA is considering small, sequential groups receiving increasing doses, with a starting dose supported by available data and no higher than 10 milligrams per kilogram. It is asking for feedback on these approaches, rather than announcing a trial protocol.
For safety, the FDA is seeking information on monitoring for cardiac and neurologic adverse events and other safeguards. It also asks about eligibility criteria, stopping rules, informed consent and independent safety oversight. The agency says comments may help it better understand potential uses, benefits and risks and inform approaches to development.
The request follows federal research activity on ibogaine and related compounds. The FDA says it has allowed an early-phase study of noribogaine hydrochloride, an ibogaine derivative, to proceed under an Investigational New Drug application as a potential treatment for alcohol use disorder. Separately, the Department of Health and Human Services says ARPA-H is funding early-phase trials to collect safety and efficacy data, while the National Institute on Drug Abuse is funding research on ibogaine for potential treatment of opioid use disorder.
How Trial Safeguards Could Shape Research
The FDA’s request addresses a practical hurdle for studying a compound that the agency says raises serious safety concerns: how to investigate potential benefits while protecting participants. Feedback on dosing, monitoring, eligibility and stopping rules could help inform what safeguards are considered in early-phase studies. Those design choices matter because early trials are intended to assess safety and gather initial evidence, not establish broad clinical benefit.
The request also gives patients, researchers, clinicians and other stakeholders a formal channel to submit relevant evidence and concerns to the FDA. Federal agencies have identified adults with opioid use disorder and post-traumatic stress disorder as initial populations for federally supported research, citing available data and the seriousness of those conditions. That prioritization describes research plans; it is not a finding that ibogaine treats either condition.
ibogaine research safety monitoring devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Federal Psychedelic Research Steps
The FDA describes the request as its latest action connected to President Donald Trump’s April 2026 executive order on accelerating medical treatments for serious mental illness, which directed agencies to accelerate research into psychedelic medicine. In July 2026, the FDA finalized guidance for industry, Psychedelic Drugs: Considerations for Clinical Investigations, outlining general considerations for sponsors developing psychedelic drugs.
The FDA’s current request concerns ibogaine drug products and possible early-phase trial approaches. Its mention of a study of noribogaine hydrochloride refers to a derivative, and the agency identifies that study as being for potential treatment of alcohol use disorder. These activities form part of a broader federal effort to collect evidence; they do not amount to FDA approval of ibogaine or noribogaine for treatment.
““With ibogaine, there are important scientific questions as well as serious safety concerns.””
— Michael Davis, director of the FDA Center for Drug Evaluation and Research
Questions the Request Leaves Open
The FDA has not specified a final trial design, selected a dose for a particular study or announced new clinical findings in this request. It is also not yet clear how the agency will weigh public submissions or whether the information will lead to changes in guidance, additional studies or particular safeguards.
The request does not establish ibogaine’s safety or effectiveness for opioid use disorder, PTSD or any other condition. The scope and results of future research remain uncertain, including what evidence might support further development. The FDA’s description of serious safety concerns underscores why proposed monitoring and oversight are part of the questions before it.
Comments Close November 20
The FDA says the public has 45 days after publication in the Federal Register to submit comments, data or information. The agency lists Friday, November 20, 2026, as the closing date and says late comments will not be considered. Submissions can be made electronically through Regulations.gov by searching for Docket No. FDA-2026-N-10429, or sent in writing to the FDA Dockets Management Staff at 5630 Fishers Lane, Room 1061, Rockville, Maryland 20852.
After the comment period, the agency may use the submissions to inform its understanding of ibogaine’s potential uses, benefits and risks and approaches to drug development. The announcement does not set a date for a decision on trial design or a further FDA action.
Key Questions
What is the FDA asking the public to comment on?
The agency seeks comments and data on possible early-phase ibogaine trial designs, including patient populations, dosing, safety monitoring, eligibility, stopping rules, informed consent and independent oversight.
Does this mean ibogaine is FDA-approved?
No. The request is about gathering input to inform research and drug development. It does not approve ibogaine as a treatment or establish its safety or effectiveness for any condition.
What dose is the FDA considering?
The FDA asks for input on a possible starting dose supported by available data and not exceeding 10 mg/kg, alongside small, sequential dose-ascending groups. It has not announced a final dose or trial protocol.
When and how can comments be submitted?
The FDA lists November 20, 2026, as the deadline. Comments can be submitted electronically at Regulations.gov under Docket No. FDA-2026-N-10429 or sent to the agency’s Dockets Management Staff in Rockville, Maryland.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
